Dna Or Rna Fragments Or Modified Forms Thereof (e.g., Genes, Etc.) Patents (Class 536/23.1)
  • Patent number: 11918600
    Abstract: Provided is a siRNA for inhibiting HBV gene expression, including a sense strand and an antisense strand. The sense strand includes a nucleotide sequence 1, and the antisense strand includes a nucleotide sequence 2; the nucleotide sequence 1 and the nucleotide sequence 2 are at least partially reversely complementary to form a double-stranded region; the nucleotide sequence 1 and the nucleotide sequence shown in SEQ ID NO: 1 are equal in length, and no more than 3 nucleotide differences are generated; the nucleotide sequence 2 and the nucleotide sequence shown in SEQ ID NO: 2 are equal in length, and no more than 3 nucleotide differences are generated; nucleotides of the 7th, 8th, and 9th bits of the nucleotide sequence 1 and the 2nd, 6th, 14th, and 16th of the nucleotide sequence 2 are fluoro-modified nucleotides. Also provided are a pharmaceutical composition and a conjugate containing the siRNA.
    Type: Grant
    Filed: August 20, 2019
    Date of Patent: March 5, 2024
    Assignee: SUZHOU RIBO LIFE SCIENCE CO., LTD.
    Inventors: Hongyan Zhang, Shan Gao, Daiwu Kang, Gengrong Chen
  • Patent number: 11918648
    Abstract: The present disclosure describes combination therapies comprising an antagonist of Programmed Death 1 receptor (PD-1) and a Toll-like receptor 9 (TLR9) agonist that is a CpG-C type oligonucleotide, and the use of the combination therapies for the treatment of cancer.
    Type: Grant
    Filed: August 21, 2020
    Date of Patent: March 5, 2024
    Assignees: MERCK SHARP & DOHME LLC, TRISALUS LIFE SCIENCES, INC.
    Inventors: Ying Yu, Andrew Evan Denker, Svetlana Sadekova, Uyen Truong Phan, Robert A. Kastelein, David Ross Kaufman, Robert L. Coffman, Cristiana Guiducci, Robert S. Janssen
  • Patent number: 11913080
    Abstract: The present disclosure provides methods and compositions of modified oligonucleotide primer and probe combinations, structurally modified with locked nucleic acids, quenchers, and dyes, effective to detect tumor-derived Human Papilloma Virus (HPV) and tumor-derived Epstein-Barr virus (EBV) and, especially, to distinguish viral DNA derived from tumors from viral DNA derived from infectious viral particles.
    Type: Grant
    Filed: February 15, 2022
    Date of Patent: February 27, 2024
    Assignee: The University of North Carolina at Chapel Hill
    Inventors: Gaorav Gupta, Bhishamjit S. Chera, Sunil Kumar
  • Patent number: 11905532
    Abstract: Compositions and methods for the storage, organization, access, and retrieval of information encoded by sequence controlled polymers such as data storage nucleic acids are provided. In some embodiments, organization, storage, and/or selective retrieval of the data is facilitated by hybridization of barcode sequence of the sequence controlled polymer to the reverse complementary sequence of an oligonucleotide. The plurality of oligonucleotides can be arrayed using a known organization scheme, and selectively capture and localize the corresponding sequence controlled polymer. In some embodiments, the compositions and methods utilize recombinant bacteriophage, typically featuring a minigenome having a bacteriophage origin of replication and packaging signal separated from a data storage sequence by barcodes.
    Type: Grant
    Filed: June 25, 2020
    Date of Patent: February 20, 2024
    Assignee: MASSACHUSETTS INSTITUTE OF TECHNOLOGY
    Inventor: Tyson Robert Shepherd
  • Patent number: 11898186
    Abstract: A method for in vitro transcription of a DNA template into RNA includes providing a mixture containing a buffer substance, ribonucleoside triphosphates (NTPs), one or more magnesium salts in a concentration of from about 2 mM to about 60 mM, the DNA template, and a recombinant RNA polymerase, and incubating the reaction mixture at from about 25° C. to about 40° C. for from about 1 hour to about 12 hours thereby producing the RNA. A method for in vitro transcription includes providing a DNA template and a cap analogue that binds to ?1 and/or +1 nucleotides of promoter for in vitro transcription, thus producing more full length mRNAs, allowing for more flexibility on the choice of first mRNA base, and providing +2 position open for custom sequence.
    Type: Grant
    Filed: December 20, 2022
    Date of Patent: February 13, 2024
    Assignee: GENSCRIPT USA INC.
    Inventors: Cheng-Hsien Wu, Fengmei Pi, Robert Dempcy, Shambhavi Shubham, Kristine Bielecki, Aaron Ball
  • Patent number: 11898199
    Abstract: The present disclosure provides, among other things, methods of screening for colorectal cancer, methods of screening for advanced adenoma, methods of screening for the presence of either colorectal cancer or advanced adenoma (or both), and compositions related thereto. In various embodiments, the present disclosure provides methods for colorectal cancer and/or advanced adenoma screening that includes analysis of methylation status of one or more methylation biomarkers, and compositions related thereto. In various embodiments, the present disclosure provides methods for colorectal cancer and/or advanced adenoma screening that include screening methylation status of one or more methylation biomarkers in cfDNA, e.g., in ctDNA. In various embodiments, the present disclosure provides methods for colorectal cancer and/or advanced adenoma screening that include screening methylation status of one or more methylation biomarkers in cfDNA, e.g., in ctDNA, using MSRE-qPCR.
    Type: Grant
    Filed: November 11, 2019
    Date of Patent: February 13, 2024
    Assignee: Universal Diagnostics, S.A.
    Inventors: Marko Bitenc, Kristi Kruusmaa, Juan Martinez-Barea, Christian Hense, Marko Chersicola, Primo{hacek over (z)} Knap
  • Patent number: 11879140
    Abstract: A composition of matter comprising a DNAzyme molecule capable of mediating cleavage of p21 mRNA corresponding to SEQ ID NO: 1, wherein said DNAzyme molecule comprises a nucleic acid sequence at least 80% identical to the nucleic acid sequence set forth in any one of SEQ ID NOs: 23, 29, 33-38, 40, 42, 45-48, 53-60, 63-65, 69-74 or 78, is disclosed. Methods of eradicating senescent cells or cancer cells, as well as methods of treating senescence-associated diseases or disorders, cancer, and fibrotic diseases and disorders are also disclosed.
    Type: Grant
    Filed: June 28, 2023
    Date of Patent: January 23, 2024
    Assignee: 1E THERAPEUTICS LTD.
    Inventors: Noam Pilpel, Yossi Ovadya, Dina Raichlin, Etti Katz-Kadosh, Alaa Knany, Ella Gillis, Noam Borovsky, Anastasia Shapiro, Ido Bachelet
  • Patent number: 11874213
    Abstract: Aspects of the present disclosure include methods for adjusting sensitivity of a photodiode in a light detection system. Methods according to certain embodiments include detecting light with a light detection system having a photodiode and an amplifier, determining responsivity of the photodiode over a plurality of wavelengths of light and adjusting one or more parameters of the amplifier in response to the responsivity of the photodiode over the plurality of wavelengths of light. Systems (e.g., particle analyzers) having a light source and a light detection system that includes a photodiode and an amplifier for practicing the subject methods are also described. Non-transitory computer readable storage medium are also provided.
    Type: Grant
    Filed: March 15, 2021
    Date of Patent: January 16, 2024
    Assignee: BECTON, DICKINSON AND COMPANY
    Inventors: Timothy W. Petersen, Pierce O. Norton, Henry Lankila, Eric D. Diebold
  • Patent number: 11873489
    Abstract: The present invention relates to products and compositions and their uses. In particular the invention relates to nucleic acid products that interfere with target gene expression or inhibit target gene expression and therapeutic uses of such products.
    Type: Grant
    Filed: November 13, 2018
    Date of Patent: January 16, 2024
    Assignee: SILENCE THERAPEUTICS GMBH
    Inventors: Lucas Bethge, Judith Hauptmann, Christian Frauendorf, Adrien Weingärtner
  • Patent number: 11866754
    Abstract: The present disclosure relates to cap analogs, which can result in high levels of capping efficiency and transcription and improved translation efficiencies. The present disclosure also relates to methods useful for preparing cap analogs and using mRNA species containing such analogs, as well as kits containing the novel cap analogs.
    Type: Grant
    Filed: October 17, 2016
    Date of Patent: January 9, 2024
    Assignee: ModernaTX, Inc.
    Inventors: Gabor Butora, Matthew Stanton, Edward John Miracco
  • Patent number: 11864740
    Abstract: The present disclosure provides systems, methods, devices, and kits for analysis of vaginal biological samples. A device for the analysis of vaginal biological samples can include a sample collector, an extractor, and an assay cartridge. A method for the analysis of vaginal biological samples can include detecting the presence or absence of a pathology, a disease, an immune disorder, a reproductive disorder of a subject. The method may further comprise preserving, storing, or transporting the vaginal biological samples. A kit for the analysis of vaginal biological samples can include probe, reagents and instructions for detecting a nucleic acid in the vaginal biological samples.
    Type: Grant
    Filed: August 15, 2022
    Date of Patent: January 9, 2024
    Assignee: NEXTGEN JANE, INC.
    Inventors: Ridhi Tariyal, Stephen K. Gire
  • Patent number: 11851649
    Abstract: Aspects of the invention described herein relate to methods of making and using inducible promoters for transgene expression. The inducible promoters are derived from the NFAT-RE inducible system and are used to improve or enhance T cell survival and proliferation.
    Type: Grant
    Filed: May 15, 2018
    Date of Patent: December 26, 2023
    Assignee: Seattle Children's Hospital
    Inventors: Jia Wei, Michael C. Jensen
  • Patent number: 11851661
    Abstract: The present invention relates to polypeptide expression systems and methods of using the same.
    Type: Grant
    Filed: April 17, 2019
    Date of Patent: December 26, 2023
    Assignee: Genentech, Inc.
    Inventors: Isidro Hotzel, Yonglei Shang
  • Patent number: 11840721
    Abstract: The present disclosure generally relates to the field of microbial pathogen detection and identification utilizing genomic sequence recognition.
    Type: Grant
    Filed: April 2, 2018
    Date of Patent: December 12, 2023
    Assignee: HelixBind, Inc.
    Inventors: Alon Singer, Ranjit Prakash, Jork Nolling
  • Patent number: 11833168
    Abstract: Provided are compounds, methods, and pharmaceutical compositions for increasing the amount or activity of STMN2 RNA in a cell or animal, and in certain embodiments increasing the amount of STMN2 protein in a cell or animal. Such compounds, methods, and pharmaceutical compositions are useful to ameliorate at least one symptom of a neurodegenerative disease. Such symptoms include ataxia, neuropathy, synaptic dysfunction, deficits in cognition, and decreased longevity. Such neurodegenerative diseases include amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), Alzheimer's disease (AD), and dementia with Lewy bodies (DLB).
    Type: Grant
    Filed: June 14, 2019
    Date of Patent: December 5, 2023
    Assignees: Ionis Pharmaceuticals, Inc., Ludwig Institute For Cancer Research
    Inventors: Huynh-Hoa Bui, Don W. Cleveland, Ze'ev Melamed
  • Patent number: 11834720
    Abstract: Described herein are novel SCCmec right extremity junction (MREJ) sequences for the detection and/or identification of methicillin-resistant Staphylococcus aureus (MRSA). Disclosed are methods and compositions based on DNA sequences for the specific detection of MREJ sequences designated types xi, xii, xiii, xiv, xv, xvi, xvii, xviii, xix, and xx for diagnostic purposes and/or epidemiological typing.
    Type: Grant
    Filed: October 10, 2006
    Date of Patent: December 5, 2023
    Assignee: GENEOHM SCIENCES, INC.
    Inventors: Ann Huletsky, Richard Giroux
  • Patent number: 11810646
    Abstract: Methods for design of genetic circuits are provided.
    Type: Grant
    Filed: February 13, 2020
    Date of Patent: November 7, 2023
    Assignee: The Regents of the University of California
    Inventors: Chunbo Lou, Tae Seok Moon, Virgil Rhodius, Brynne Stanton, Alvin Tasmir, Karsten Temme, Chris Voigt
  • Patent number: 11795462
    Abstract: The present invention provides an oligonucleotide comprising the sequence 5?-GGAACAGTTCGTCCATGGC-3? (SEQ ID NO:2) for use in the treatment of inflammatory bowel disease in a human subject, wherein individual doses of from 100 mg to 350 mg of said oligonucleotide are administered to the subject on at least four separate occasions, wherein the separate occasions are each a week apart.
    Type: Grant
    Filed: May 9, 2018
    Date of Patent: October 24, 2023
    Assignee: Index Pharmaceuticals AB
    Inventors: Arezou Zargari, Charlotte Admyre, Pernilla Sandwall, Thomas Knittel, Peter Zerhouni
  • Patent number: 11781146
    Abstract: The present invention provides mammalian cell expression vectors that impart to mammalian host cells an ability to produce high levels of foreign gene-derived proteins. A ubiquitously acting chromatin opening element (UCOE) is introduced into an expression vector that has a plasmid DNA integrated into a transcriptional hot spot on the chromosome of a dihydrofolate reductase gene-deficient host cell so that it allows for selection of strains that grow in hypoxanthine-thymidine (hereinafter denoted as HT)-free medium, whereby transformants will produce a protein of interest in increased amounts.
    Type: Grant
    Filed: May 13, 2019
    Date of Patent: October 10, 2023
    Assignees: NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY, FUSO PHARMACEUTICAL INDUSTRIES, LTD.
    Inventors: Yasuhiko Suzuki, Miki Nakagawa, Yayoi Kameda, Satoru Konnai, Tomohiro Okagawa, Naoya Maekawa, Shinya Goto, Yamato Sajiki, Kazuhiko Ohashi, Shiro Murata, Yuzuru Kitahara, Keiichi Yamamoto
  • Patent number: 11781186
    Abstract: The invention displays aflatoxin B1 (AFB1) detection kit and AFB1 detection method. The invention belongs to the technical field of detecting harmful substances. The AFB1 detection kit was fabricated with DNA walker structure, endonuclease, hairpin H1 and H2. The AFB1 detection kit has benefits of high sensitivity and short detection time based on signal amplification strategy of DNA Walker structure and hyperbranched fluorescent nanotrees. The present invention can realize high sensitive and rapid detection of AFB1.
    Type: Grant
    Filed: January 21, 2021
    Date of Patent: October 10, 2023
    Assignee: QINGDAO AGRICULTURAL UNIVERSITY
    Inventors: Qingli Yang, Qi Wang, Wei Wu, Fangyuan Zhao, Xiudan Hou, Haiyan Zhao, Yinglian Zhu, Zhaojie Li
  • Patent number: 11773380
    Abstract: Mutant polymerases are provided that have improved ability to incorporate modified nucleotides, including 3?-OH unblocked reversible terminators. The mutant polymerases may be used in a variety of applications, such as for polynucleotide sequencing, primer extension reactions, and template-independent enzymatic oligonucleotide synthesis.
    Type: Grant
    Filed: August 24, 2022
    Date of Patent: October 3, 2023
    Assignee: Agilent Technologies, Inc.
    Inventors: Michelle Cayouette, Jeffrey Fox, Connie Hansen, Holly Hogrefe, Weidong Wu
  • Patent number: 11760997
    Abstract: Compositions, systems, and methods for the display of analytes such as biomolecules are described. Display of analytes is achieved by coupling of the analytes to displaying molecules that are configured to associate with surfaces or interfaces. Arrays of analytes may be formed from the described systems for utilization in assays and other methods.
    Type: Grant
    Filed: October 28, 2022
    Date of Patent: September 19, 2023
    Assignee: Nautilus Subsidiary, Inc.
    Inventors: Tural Aksel, Stephen Hendricks, Elvis Ikwa, Pierre Indermuhle, Sadie Ingle, Christina Inman, Parag Mallick, Torri Elise Rinker, Steven Tan
  • Patent number: 11739389
    Abstract: The present invention generally relates to methods and agents for identifying and/or classifying microbes (especially bacteria), yeast organisms and filamentous fungi. In particular, the present invention concerns the discovery of unique single nucleotide polymorphisms (SNPs) in bacterial 16S ribosomal RNA (16S rRNA) and yeast organism and filamentous fungi 18S ribosomal RNA, and methods of classifying and/or identifying bacteria, yeast organisms and/or filamentous fungi in a sample based on the presence of one or more of those SNPs. The present invention also concerns probes, primers and kits that are useful in those methods.
    Type: Grant
    Filed: May 17, 2018
    Date of Patent: August 29, 2023
    Assignee: Microbio Pty Ltd
    Inventor: Flavia Huygens
  • Patent number: 11739359
    Abstract: A universal template strand built with universal base analogs is used as a template for polynucleotide synthesis. The universal template strand can hybridize to any sequence of nucleotides. A new polynucleotide is synthesized by using a polymerase to extend a primer hybridized to the universal template strand. Unlike primer extension in polymerase chain reactions, base pairing with nucleotides in the template strand does not specify the sequence of the new polynucleotide. Instead, the sequence of the new polynucleotide is specified by the order of addition of protected nucleotides. After addition of a single species of protected nucleotide, the blocking group is removed and another protected nucleotide is added. The order of nucleotide addition can be varied to create any sequence. After synthesis, the polynucleotide can be dehybridized from the universal template strand. The universal template strand may then be reused to synthesize a different polynucleotide.
    Type: Grant
    Filed: May 1, 2020
    Date of Patent: August 29, 2023
    Assignee: MICROSOFT TECHNOLOGY LICENSING, LLC
    Inventors: Bichlien Nguyen, Jake Smith, Robert Carlson, Karin Strauss
  • Patent number: 11732267
    Abstract: A nucleic acid aptamer having binding affinity to A/H1N1pdm09 influenza virus, agents comprising the aptamer, and methods using the aptamer are provided.
    Type: Grant
    Filed: October 29, 2021
    Date of Patent: August 22, 2023
    Assignee: ARKRAY, Inc.
    Inventor: Misaki Oga
  • Patent number: 11725233
    Abstract: Method and systems for identifying and distinguishing subjects using a biochip are described. Biochips comprising subject specific features comprising multiple non-overlapping probes are disclosed.
    Type: Grant
    Filed: November 15, 2016
    Date of Patent: August 15, 2023
    Assignee: REVERE BIOSENSORS, LLC
    Inventors: Robert Charles Kain, Richard Shen
  • Patent number: 11725208
    Abstract: The present disclosure provides half duplex compounds comprising a first oligomeric compound and a second, shorter, oligomeric compound, wherein the first oligomeric compound is complementary to a target nucleic acid and the second oligomeric compound is complementary to the first oligomeric compound. In certain embodiments, the compounds disclosed herein are useful for modulating the expression of extra-hepatic target nucleic acids.
    Type: Grant
    Filed: December 14, 2018
    Date of Patent: August 15, 2023
    Assignee: Ionis Pharmaceuticals, Inc.
    Inventors: Michael Oestergaard, Punit P. Seth, Frank Rigo, Chrissa A. Dwyer
  • Patent number: 11713468
    Abstract: The present invention provides polynucleotide vectors for high expression of heterologous genes. Some vectors further comprise novel elements that further improve expression. The gene transfer systems can be used in methods, for example, gene expression, bioprocessing, gene therapy, insertional mutagenesis, or gene discovery.
    Type: Grant
    Filed: August 2, 2018
    Date of Patent: August 1, 2023
    Assignee: DNA TWOPOINTO INC.
    Inventors: Jeremy Minshull, Maggie Lee
  • Patent number: 11702689
    Abstract: This disclosure describes a technique for performing random access in a pool of polynucleotides by using one unique primer and one homopolymer primer to selectively amplify some but not all of the polynucleotides in the pool. The polynucleotides are synthesized by a template independent polymerase such as terminal deoxynucleotide transferase (TdT) rather than by phosphoramidite synthesis. Enzymatic synthesis efficiently creates homopolymer sequences through unregulated synthesis. Use of one homopolymer primer instead of two unique primers decreases the complexity, time, and cost of synthesizing the polynucleotides. Use of a unique primer provides a sequence that can be varied to uniquely identify multiple different groups of polynucleotides. This enables random access by polymerase chain reaction (PCR) amplification while still benefitting from the efficiency of homopolymer synthesis. The polynucleotides may include payload regions that use a sequence of nucleotides to encode digital data.
    Type: Grant
    Filed: April 24, 2020
    Date of Patent: July 18, 2023
    Assignee: MICROSOFT TECHNOLOGY LICENSING, LLC
    Inventors: Yuan-Jyue Chen, Bichlien Nguyen
  • Patent number: 11697850
    Abstract: This invention relates to nucleotide polymorphisms in the human Apo(a) gene and to the use of Apo(a) nucleotide polymorphisms in identifying whether a human subject will respond or not to treatment with acetylsalicylic acid.
    Type: Grant
    Filed: December 16, 2019
    Date of Patent: July 11, 2023
    Assignees: The Brigham and Women's Hospital, Inc., Celera Corporation
    Inventors: Paul M. Ridker, Daniel Chasman, Dov Shiffman
  • Patent number: 11692213
    Abstract: Provided herein are methods and compositions for depleting targeted nucleic acid sequences from a sample, enriching for sequences of interest from a sample, and/or partitioning of sequences from a sample. The methods and compositions are applicable to biological, clinical, forensic, and environmental samples.
    Type: Grant
    Filed: August 3, 2020
    Date of Patent: July 4, 2023
    Assignee: ARC BIO, LLC
    Inventors: Meredith L. Carpenter, Carlos D. Bustamante, Stephane B. Gourguechon
  • Patent number: 11680283
    Abstract: Methods of uniquely labeling or barcoding molecules within a nucleus, a plurality of nuclei, a cell, a plurality of cells, and/or a tissue are provided. Kits for uniquely labeling or barcoding molecules within a nucleus, a plurality of nuclei, a cell, a plurality of cells, and/or a tissue are also provided. The molecules to be labeled may include, but are not limited to, RNAs and/or cDNAs.
    Type: Grant
    Filed: September 21, 2018
    Date of Patent: June 20, 2023
    Assignee: UNIVERSITY OF WASHINGTON
    Inventors: Georg Seelig, Alexander B. Rosenberg, Charles Roco
  • Patent number: 11679132
    Abstract: The present invention relates to a method of using a receptor (e.g., chimeric antigen receptor—CAR) that activates an immune response upon binding a cancer cell ligand in conjunction with a target-binding molecule that targets a protein or molecule for removal or neutralization to generate enhanced anti-cancer immune cells. The present invention also relates to engineered immune cells having enhanced therapeutic efficacy and uses thereof.
    Type: Grant
    Filed: July 12, 2022
    Date of Patent: June 20, 2023
    Assignee: NATIONAL UNIVERSITY OF SINGAPORE
    Inventors: Dario Campana, Takahiro Kamiya
  • Patent number: 11676682
    Abstract: Disclosed herein are methods of determining the sequence and/or positions of modified bases in a nucleic acid sample present in a circular molecule with a nucleic acid insert of known sequence comprising obtaining sequence data of at least two insert-sample units. In some embodiments, the methods comprise obtaining sequence data using circular pair-locked molecules. In some embodiments, the methods comprise calculating scores of sequences of the nucleic acid inserts by comparing the sequences to the known sequence of the nucleic acid insert, and accepting or rejecting repeats of the sequence of the nucleic acid sample according to the scores of one or both of the sequences of the inserts immediately upstream or downstream of the repeats of the sequence of the nucleic acid sample.
    Type: Grant
    Filed: November 1, 2019
    Date of Patent: June 13, 2023
    Assignee: Industrial Technology Research Institute
    Inventors: Chao-Chi Pan, Jenn-Yeh Fann, Chung-Fan Chiou, Hung-Chi Chien, Hui-Ling Chen
  • Patent number: 11672757
    Abstract: Hot melt extrusion is disclosed as a process for forming vaginal drug delivery films. The methods involve extruding a composition comprising one or more active pharmaceutical ingredients and one or more polymer carriers at an elevated temperature through a die to thereby provide the film. Films prepared by hot melt extrusion are also described.
    Type: Grant
    Filed: June 28, 2018
    Date of Patent: June 13, 2023
    Assignee: UNIVERSITY OF PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
    Inventors: Lisa Cencia Rohan, Galit Regev
  • Patent number: 11666040
    Abstract: Mice, embryos, cells, and tissues having a restricted immunoglobulin heavy chain locus and an ectopic sequence encoding one or more ADAM6 proteins are provided. In various embodiments, mice are described that have humanized endogenous immunoglobulin heavy chain loci and are capable of expressing an ADAM6 protein or ortholog or homolog or functional fragment thereof that is functional in a male mouse. Mice, embryos, cells, and tissues having an immunoglobulin heavy chain locus characterized by a single human VH gene segment, a plurality of human DH gene segments and a plurality of human JH gene segments and capable expressing an ADAM6 protein or ortholog or homolog or functional fragment thereof are also provided.
    Type: Grant
    Filed: April 15, 2020
    Date of Patent: June 6, 2023
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Lynn Macdonald, Sean Stevens, Andrew J. Murphy, Margaret Karow, John McWhirter
  • Patent number: 11666653
    Abstract: The present invention provides a modified RNAi agent comprising a sense strand and an antisense strand, wherein the antisense strand targets an HBV mRNA; all of the nucleotide sugars of the RNAi agent are 2?-modified; and at least one of the sense and antisense strands is conjugated to at least one targeting ligand that comprises two or more building blocks connected to a biantennary or triantennary branched linker, optionally via one or more linking groups.
    Type: Grant
    Filed: November 23, 2021
    Date of Patent: June 6, 2023
    Assignee: ALNYLAM PHARMACEUTICALS, INC.
    Inventors: Muthiah Manoharan, Kallanthottathil G. Rajeev, Jayaprakash K. Nair, Martin Maier
  • Patent number: 11667972
    Abstract: Next Generation DNA sequencing promises to revolutionize clinical medicine and basic research. However, while this technology has the capacity to generate hundreds of billions of nucleotides of DNA sequence in a single experiment, the error rate of approximately 1% results in hundreds of millions of sequencing mistakes. These scattered errors can be tolerated in some applications but become extremely problematic when “deep sequencing” genetically heterogeneous mixtures, such as tumors or mixed microbial populations. To overcome limitations in sequencing accuracy, a method Duplex Consensus Sequencing (DCS) is provided. This approach greatly reduces errors by independently tagging and sequencing each of the two strands of a DNA duplex. As the two strands are complementary, true mutations are found at the same position in both strands. In contrast, PCR or sequencing errors will result in errors in only one strand.
    Type: Grant
    Filed: August 2, 2021
    Date of Patent: June 6, 2023
    Assignee: UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION
    Inventors: Jesse Salk, Lawrence A. Loeb, Michael Schmitt
  • Patent number: 11661601
    Abstract: Provided are methods for increasing the amount or activity of FMR1 RNA, and in certain instances of increasing the amount of FMRP protein, in an animal Such methods are useful to prevent or ameliorate at least one symptom of a Fragile X-Spectrum disorder. Such Fragile X-Spectrum disorders include FXS, FXTAS, and FXPOI.
    Type: Grant
    Filed: March 22, 2019
    Date of Patent: May 30, 2023
    Assignees: IONIS PHARMACEUTICALS, INC., THE REGENTS OF THE UNIVERSITY OF MICHIGAN
    Inventors: Frank Rigo, Peter Todd, Caitlin Rodriguez
  • Patent number: 11661603
    Abstract: This disclosure relates to oligonucleotides, compositions and methods useful for reducing ALDH2 expression, particularly in hepatocytes. Disclosed oligonucleotides for the reduction of ALDH2 expression may be double-stranded or single-stranded, and may be modified for improved characteristics such as stronger resistance to nucleases and lower immunogenicity. Disclosed oligonucleotides for the reduction of ALDH2 expression may also include targeting ligands to target a particular cell or organ, such as the hepatocytes of the liver, and may be used to treat alcoholism and related conditions.
    Type: Grant
    Filed: January 15, 2019
    Date of Patent: May 30, 2023
    Assignee: Dicerna Pharmaceuticals, Inc.
    Inventor: Utsav Saxena
  • Patent number: 11650202
    Abstract: Methods are provided for detecting a single compound analyte immobilized to a solid substrate by serially contacting and removing different probes to the same analyte.
    Type: Grant
    Filed: February 9, 2022
    Date of Patent: May 16, 2023
    Assignee: APTON BIOSYSTEMS, INC.
    Inventors: Bryan P. Staker, Niandong Liu, Bart Lee Staker, Michael David McLaughlin
  • Patent number: 11648267
    Abstract: Disclosed herein are methods and compositions for inactivating CCR-5 genes, using zinc finger nucleases (ZFNs) comprising a zinc finger protein and a cleavage domain or cleavage half-domain. Polynucleotides encoding ZFNs, vectors comprising polynucleotides encoding ZFNs, such as adenovirus (Ad) vectors, and cells comprising polynucleotides encoding ZFNs and/or cells comprising ZFNs are also provided.
    Type: Grant
    Filed: July 3, 2018
    Date of Patent: May 16, 2023
    Assignee: Sangamo Therapeutics, Inc.
    Inventors: Dale Ando, Michael C. Holmes, Gary Ka Leong Lee
  • Patent number: 11643671
    Abstract: Described herein are systems and methods for treating, inhibiting, or ameliorating X-linked disorders including Wiskott-Aldrich Syndrome (WAS) and X-linked thrombocytopenia (XLT) in subjects that have been identified or selected as being ones that would benefit from a therapy to treat, inhibit, or ameliorate WAS or XLT. The systems include nuclease and vector donor constructs configured for co-delivery to modify endogenous WAS locus.
    Type: Grant
    Filed: April 19, 2018
    Date of Patent: May 9, 2023
    Assignee: Seattle Children's Hospital
    Inventors: David J. Rawlings, Iram Khan
  • Patent number: 11643647
    Abstract: A system for DNA gene assembly that utilizes a DNA symbol library and a DNA linker library. The symbol library has a number of DNA symbols each having a first overhanging end and a second overhanging end different than and non-complimentary to the first end, the first and second ends being the same nucleotides for each DNA symbol. The linker library has pairs of DNA linkers, a first linker of a pair having a first end and a second end and a second linker of the pair having a first end and a second end, the first end of the first linker being the same nucleotides for each first linker and the second end of the second linker being the same nucleotides for each second linker, wherein the second end of the first linker and the first end of the second linker have complementary nucleotides. The first linker joins to the first end of a DNA symbol and the second linker joins to the second end of another DNA symbol.
    Type: Grant
    Filed: June 15, 2021
    Date of Patent: May 9, 2023
    Assignee: SEAGATE TECHNOLOGY LLC
    Inventors: Tim Rausch, Walter R Eppler, Gemma Mendonsa
  • Patent number: 11613754
    Abstract: Disclosed are polynucleotides, compositions, and methods related to RNA interference (RNAi). The disclosed polynucleotides, compositions, and methods may be utilized for treating diseases and disorders through RNAi. Particular disclosed are toxic RNAi active seed sequences and methods of using toxic RNAi active sequences for killing cancer cells. The disclosed toxic RNAi active seed sequences preferentially target and inhibit the expression of multiple essential genes for cell survival and/or growth through a process called “death-induced by survival gene elimination” or “DISE.
    Type: Grant
    Filed: February 20, 2018
    Date of Patent: March 28, 2023
    Assignee: Northwestern University
    Inventors: Marcus E. Peter, William E. Putzbach, Andrea E. Murmann, Monal Patel, Quan Gao
  • Patent number: 11603529
    Abstract: Provided herein are RNAi molecules for treating Huntington's disease. Further provided herein are expression cassettes, vectors (e.g., rAAV, recombinant adenoviral, recombinant lentiviral, and recombinant HSV vectors), cells, viral particles, and pharmaceutical compositions containing the RNAi. Yet further provided herein are methods and kits related to the use of the RNAi, for example, to treat Huntington's disease.
    Type: Grant
    Filed: September 21, 2018
    Date of Patent: March 14, 2023
    Assignee: GENZYME CORPORATION
    Inventors: Catherine R. O'Riordan, Adam Palermo, Brenda Richards, Lisa M. Stanek
  • Patent number: 11603534
    Abstract: Provided are promoters and a method of producing L-amino acid using the same.
    Type: Grant
    Filed: March 15, 2019
    Date of Patent: March 14, 2023
    Assignee: CJ CHEILJEDANG CORPORATION
    Inventors: Jee Yeon Bae, Chang Il Seo, Inhwa Yoo, Hye Ryun Yoo, So Young Kim, Yong Uk Shin
  • Patent number: 11597745
    Abstract: A ?-modified phosphoric acid compound precursor that inhibits the progress of a phosphorylation reaction having a partial structure represented by where A1 represents —SR1, —S—S—R1, —SeR1, or —X, where X is a halogen selected from fluoro, chloro, bromo, and iodo; R1 represents hydrogen, an alkyl group having 1 to 20 carbon atoms, or the like; L1 represents hydrogen, an alkyl group having 1 to 20 carbon atoms, or the like; L2 represents an alkyl group having 1 to 20 carbon atoms, or the like; L1 and L2 may be linked to each other to form a 4 to 6-membered ring structure; L1 and L2 may each have a substituent; and the symbol * represents a bond to be bonded to a phosphate group by phosphorylation. Further, provided are a reaction inhibitor and a medicine, each of which includes the ?-modified phosphoric acid compound precursor.
    Type: Grant
    Filed: March 8, 2019
    Date of Patent: March 7, 2023
    Assignee: Japan Science and Technology Agency
    Inventors: Hiroshi Abe, Yasuaki Kimura
  • Patent number: 11597977
    Abstract: The present invention relates to new methods for diagnosing a pregnancy-associated disorder by analyzing fetal DNA present in the mother's blood. More specifically, this invention relies on the discovery that the maspin gene is differentially methylated in fetal DNA and in maternal DNA and provides these new diagnostic methods, which distinguish fetal DNA from maternal DNA and detect prenatal disorders based on abnormalities in fetal DNA level and methylation status.
    Type: Grant
    Filed: March 2, 2020
    Date of Patent: March 7, 2023
    Assignee: The Chinese University of Hong Kong
    Inventors: Yuk Ming Dennis Lo, Wai Kwun Rossa Chiu, Stephen Siu Chung Chim, Yu-Kwan Tong, Chunming Ding
  • Patent number: 11591634
    Abstract: The present disclosure provides a novel integrated entropy-based method that combines genome-wide profiling and network analyses for diagnostic and prognostic applications. The present disclosure further provides the integration of multiomics datasets, network analyses and machine learning that enable predictions on diagnosing infectious diseases and predicting the probability that they will escape treatment/the host immune system and/or become antibiotic resistant. The present disclosure provides a primary gateway towards the development of highly accurate infectious disease prognostics.
    Type: Grant
    Filed: April 3, 2020
    Date of Patent: February 28, 2023
    Assignee: The Trustees of Boston College
    Inventors: Tim van Opijnen, Zeyu Zhu, Defne Surujon